Role of antioxidant enzymes (AOXs) and drug-metabolising enzymes (DMEs) in metabolic diseases (e.g. non-alcoholic fatty liver disease, obesity)
- In vivo and in vitro models of obesity and NAFLD
- Expression (mRNA and protein) and activity of AOXs and DMEs
- Epigenetic regulation (miRNA, DNA methylation, histone modifications)
Biological activities of compounds of natural origin (e.g. mono- and sesquiterpenes, prenylflavonoids)
- Tests of hepatotoxicity in primary cultures of hepatocytes, hepatic spheroids precision-cut liver slices, and differentiated HepaRG cells
- Effect on expression and activity of AOXs and DMEs in the in vitro models of NAFLD
- Anti-inflammatory activity of essential oils
- Antiproliferative activity of essential oils in various immortalized cell lines
|
 |
Drug metabolism studies in vitro and/or in vivo
- Identification of metabolites of drugs and other xenobiotics in animals, humans, and plants
- Preparation and incubation of precision-cut liver and intestinal slices
- Isolation and cultivation of primary cultures of hepatocytes
- Preparation of subcellular fractions (animal and human organs, plants)
- electrochemical oxidation and reduction mechanisms of natural compounds
Role of DMEs in drug interactions
- Interactions of natural substances/ food supplements with drugs – effect of drugs, dietary supplements, natural compounds and other xenobiotics on expression and activity of DMEs or antioxidant enzymes
|
|
|
 |